Business Wire

Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow

29.10.2025 11:12:00 EET | Business Wire | Press release

Share

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced today its Q3 2025 results, summarizing financial performance year-to-date ending 30 September 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029815979/en/

Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow

Year-to-Date Financial Highlights as of Q3 2025:

  • Positive free cash flow EUR 3.2 (–2.2) million, sixth consecutive quarter of cash-positive operations.
  • Revenue in constant currency EUR 56.6 (54.0) million, +4.8%.
  • EBIT in constant currency EUR 14.9 (13.0) million, +15.0%.
  • Annual recurring revenue EUR 25.1 (23.2) million, +8%.
  • Order backlog EUR 105.5 (75.1) million, +40%.

Commenting on the results for the third quarter of 2025, Padma Ravichander, CEO of Tecnotree, says:

“Tecnotree’s Q3 2025 results reflect our disciplined focus on profitable order book execution, with year-to-date operating result up 15% year on year in constant currency. Maintaining cash-positive operations for the sixth consecutive quarter with EUR 3.2 million free cash flow demonstrates the strength of our strategy and operational discipline. Tecnotree's transformation from a turnaround to a growth story is complete.

The results underscore our continued investment in expanding delivery capabilities in developed markets, including Europe and the Americas. By strengthening our local, high-skill talent and accelerating project execution, we are building a strong foundation for sustainable recurring revenue growth and long-term value creation.

The medium-term positive trajectory is evident in our order book and constant currency revenue growth (versus a negative market growth in 2025). However in this quarter, whilst there was a tailwind from last year’s cost restructuring, there were near term profit margin headwinds from US dollar weakness, as well as strategic cost deployment ahead of new contract wins.

Our AI-native digital platforms continue to gain traction globally. Strategic partnerships in Europe and the Americas extend our reach beyond traditional BSS, enabling Tier-1 operators to modernize and monetize networks faster. During the third quarter, Gartner upgraded Tecnotree’s position in its Magic Quadrant for AI in CSP Customer and Business Operations 2025 from “Niche Player” to “Visionary” for our execution capability and innovation through our Tecnotree Moments and Sensa platforms. The use of Agentic AI Chatbots enhances customer self-service, improving explainability, transparency and contextual awareness leading to greater revenue monetization. In addition, AI is not just being added to every product, AI is our product. Every module in the D-Stack has embedded intelligence help us move from AI-enabled to an AI-native BSS. Confirming the reason why Gartner Visionary IDC named Tecnotree as a Major Player for Worldwide Customer Experience Platforms for Telecommunications 2025.

We further strengthened our operational efficiency, maintaining capex at a disciplined 11.9% of sales year-to-date, well within guidance, while improving DSO to 154 days, down from 175 in H1 2025, reflecting effective working capital management.

Looking ahead, our priorities remain clear: converting backlog into cash, executing large transformation programs across Europe, Americas, and Africa, and continuing operational efficiencies. Management reiterates its full-year 2025 guidance, expecting net sales growth in constant currency of low-to-high single digit, operating result margin expansion of at least 200 basis points, and free cash flow exceeding EUR 4 million. I want to thank our employees, customers, and shareholders for their trust and continued support as we execute the next phase of Tecnotree’s strategy.”

About Tecnotree

Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company’s commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V). For more information, please visit our website www.tecnotree.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029815979/en/

Contacts

Padma Ravichander, CEO, Tecnotree
Email: marketing@tecnotree.com
www.tecnotree.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.tecnotree.c
om&esheet=54347320&newsitemid=20251029815979&lan=en-US&anchor=www.tecnotree.com&
index=2&md5=712784264c82b0e2a8b18d8ead3125f0

Prianca Ravichander, CMO & CCO, Tecnotree
Email: marketing@tecnotree.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye